Nuvation Bio (NYSE:NUVB) Shares Gap Down on Analyst Downgrade

Nuvation Bio Inc. (NYSE:NUVB) shares gapped down before the market opened on Tuesday after UBS Group lowered their price target on the stock from $10.00 to $7.00. The stock had previously closed at $5.84, but opened at $4.81. UBS Group currently has a neutral rating on the stock. Nuvation Bio shares last traded at $4.3680, with a volume of 2,245,625 shares.

NUVB has been the subject of a number of other research reports. B. Riley Financial initiated coverage on shares of Nuvation Bio in a research report on Wednesday, November 19th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Royal Bank Of Canada boosted their price target on Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday. Citizens Jmp set a $10.00 price target on Nuvation Bio in a research note on Thursday, November 20th. Finally, Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nuvation Bio has a consensus rating of “Moderate Buy” and a consensus target price of $11.44.

Key Headlines Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Nuvation says it is transitioning to a commercial-stage company with progress for Iptrozi (IBTROZI) and safusidenib, signaling revenue-led growth and a commercialization focus that investors prize. Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
• Positive Sentiment: Q4/2025 results showed revenue above consensus ($41.9M vs. $36.8M) and management highlighted strong market acceptance of its marketed oncology product(s) and an expanding partner footprint — supportive for near-term commercial revenue. Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target to $13 and kept an outperform rating, which can boost investor sentiment about upside to commercialization prospects. Benzinga: RBC raises PT to $13
• Positive Sentiment: Management outlined a first‑line growth strategy for IBTROZI with a long median duration of response (~50 months) and expanding global partnerships, reinforcing the product’s commercial potential. Nuvation Bio outlines first-line IBTROZI growth strategy
• Negative Sentiment: A law firm (Johnson Fistel) announced an investigation into potential securities-law claims involving NUVB and its executives, raising governance/legal risk that can pressure the stock if it develops. Johnson Fistel investigation notice
• Negative Sentiment: TipRanks flagged new commercialization and partner-execution risks for taletrectinib, underscoring execution challenges that could limit upside if partnerships or launches underperform. Taletrectinib commercialization risks
• Negative Sentiment: UBS cut its price target from $10 to $7 and placed a neutral rating, a downgrade that may weigh on sentiment even though other analysts remain more bullish. Benzinga: UBS lowers PT to $7

Hedge Funds Weigh In On Nuvation Bio

Hedge funds have recently made changes to their positions in the stock. Rangeley Capital LLC acquired a new stake in shares of Nuvation Bio during the 2nd quarter worth $25,000. Parallel Advisors LLC boosted its holdings in Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after acquiring an additional 2,597 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Nuvation Bio during the second quarter valued at about $29,000. Captrust Financial Advisors purchased a new stake in Nuvation Bio during the second quarter valued at about $32,000. Finally, Swiss Life Asset Management Ltd acquired a new stake in Nuvation Bio during the third quarter worth about $39,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Trading Up 8.7%

The company has a market capitalization of $1.63 billion, a PE ratio of -7.90 and a beta of 1.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.39 and a current ratio of 6.95. The business has a fifty day moving average price of $6.45 and a 200 day moving average price of $5.53.

Nuvation Bio (NYSE:NUVB) last posted its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The firm had revenue of $41.87 million during the quarter, compared to the consensus estimate of $36.82 million. Analysts expect that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.